Gemcitabine With Curcumin for Pancreatic Cancer

Phase 2CompletedNCT00192842

Rambam Health Care Campus17 enrolled

Overview

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pancreatic Cancer

Interventions

curcumin (+ gemcitabine)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * locally advanced or metastatic adenocarcinoma of the pancreas * no prior chemotherapy * performance status 0-2 * adequate hematology and chemistry Exclusion Criteria: * serious concurrent medical condition

Outcomes

Primary Outcomes

time to tumor progression

Secondary Outcomes

response rate

survival

clinical benefit

toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.